Selected research
Industry Research
Community-acquired Bacterial Pneumonia Industry Research Report 2026
Market perspective
The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Community-acquired Bacterial Pneumonia market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Community-acquired Bacterial Pneumonia market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Community-acquired Bacterial Pneumonia market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Community-acquired Bacterial Pneumonia include Takeda Pharmaceutical Company Limited, Sanofi S.A., Mylan N.V., Pfizer Inc., Bayer AG, Paratek Pharmaceuticals, Nabriva Therapeutics, Melinta Therapeutics and Lupin Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Community-acquired Bacterial Pneumonia market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Community-acquired Bacterial Pneumonia.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Community-acquired Bacterial Pneumonia Market by Company
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Mylan N.V.
Pfizer Inc.
Bayer AG
Paratek Pharmaceuticals
Nabriva Therapeutics
Melinta Therapeutics
Lupin Pharmaceuticals
Dainippon Sumitomo Pharma
Basilea Pharmaceutica International AG
Allergan plc
Community-acquired Bacterial Pneumonia Segment by Type
Oxazolidinone
Glycylcycline
Pleuromutilin Antibiotic
Ketolide
Cephalosporin
Others
Community-acquired Bacterial Pneumonia Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Community-acquired Bacterial Pneumonia Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community-acquired Bacterial Pneumonia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Community-acquired Bacterial Pneumonia and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community-acquired Bacterial Pneumonia.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Community-acquired Bacterial Pneumonia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxazolidinone
- Glycylcycline
- Pleuromutilin Antibiotic
- Ketolide
- Cephalosporin
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Mylan N.V.
- Pfizer Inc.
- Bayer AG
- Paratek Pharmaceuticals
- Nabriva Therapeutics
- Melinta Therapeutics
- Lupin Pharmaceuticals
- Dainippon Sumitomo Pharma
- Basilea Pharmaceutica International AG
- Allergan plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Community-acquired Bacterial Pneumonia by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oxazolidinone
- 2.2.3 Glycylcycline
- 2.2.4 Pleuromutilin Antibiotic
- 2.2.5 Ketolide
- 2.2.6 Cephalosporin
- 2.2.7 Others
- 2.3 Community-acquired Bacterial Pneumonia by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 Community-acquired Bacterial Pneumonia Breakdown Data by Type
- 3.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2021-2026)
- 3.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2027-2032)
4 Community-acquired Bacterial Pneumonia Breakdown Data by Application
- 4.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Application (2021-2026)
- 4.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2021-2032)
- 5.2 Global Community-acquired Bacterial Pneumonia Growth Trends by Region
- 5.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Community-acquired Bacterial Pneumonia Historic Market Size by Region (2021-2026)
- 5.2.3 Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2027-2032)
- 5.3 Community-acquired Bacterial Pneumonia Market Dynamics
- 5.3.1 Community-acquired Bacterial Pneumonia Industry Trends
- 5.3.2 Community-acquired Bacterial Pneumonia Market Drivers
- 5.3.3 Community-acquired Bacterial Pneumonia Market Challenges
- 5.3.4 Community-acquired Bacterial Pneumonia Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue
- 6.1.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue (2021-2026)
- 6.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2021-2026)
- 6.2 Global Community-acquired Bacterial Pneumonia Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Community-acquired Bacterial Pneumonia Head Office and Area Served
- 6.4 Global Community-acquired Bacterial Pneumonia Players, Product Type & Application
- 6.5 Global Community-acquired Bacterial Pneumonia Manufacturers Established Date
- 6.6 Global Community-acquired Bacterial Pneumonia Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Community-acquired Bacterial Pneumonia Market Size (2021-2032)
- 7.2 North America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
- 7.4 North America Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Community-acquired Bacterial Pneumonia Market Size (2021-2032)
- 8.2 Europe Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
- 8.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2021-2032)
- 9.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Community-acquired Bacterial Pneumonia Market Size (2021-2032)
- 10.2 South America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
- 10.4 South America Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2021-2032)
- 11.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda Pharmaceutical Company Limited
- 12.1.1 Takeda Pharmaceutical Company Limited Company Information
- 12.1.2 Takeda Pharmaceutical Company Limited Business Overview
- 12.1.3 Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.1.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio
- 12.1.5 Takeda Pharmaceutical Company Limited Recent Developments
- 12.2 Sanofi S.A.
- 12.2.1 Sanofi S.A. Company Information
- 12.2.2 Sanofi S.A. Business Overview
- 12.2.3 Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.2.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio
- 12.2.5 Sanofi S.A. Recent Developments
- 12.3 Mylan N.V.
- 12.3.1 Mylan N.V. Company Information
- 12.3.2 Mylan N.V. Business Overview
- 12.3.3 Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.3.4 Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio
- 12.3.5 Mylan N.V. Recent Developments
- 12.4 Pfizer Inc.
- 12.4.1 Pfizer Inc. Company Information
- 12.4.2 Pfizer Inc. Business Overview
- 12.4.3 Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.4.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio
- 12.4.5 Pfizer Inc. Recent Developments
- 12.5 Bayer AG
- 12.5.1 Bayer AG Company Information
- 12.5.2 Bayer AG Business Overview
- 12.5.3 Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.5.4 Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio
- 12.5.5 Bayer AG Recent Developments
- 12.6 Paratek Pharmaceuticals
- 12.6.1 Paratek Pharmaceuticals Company Information
- 12.6.2 Paratek Pharmaceuticals Business Overview
- 12.6.3 Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.6.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
- 12.6.5 Paratek Pharmaceuticals Recent Developments
- 12.7 Nabriva Therapeutics
- 12.7.1 Nabriva Therapeutics Company Information
- 12.7.2 Nabriva Therapeutics Business Overview
- 12.7.3 Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.7.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
- 12.7.5 Nabriva Therapeutics Recent Developments
- 12.8 Melinta Therapeutics
- 12.8.1 Melinta Therapeutics Company Information
- 12.8.2 Melinta Therapeutics Business Overview
- 12.8.3 Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.8.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
- 12.8.5 Melinta Therapeutics Recent Developments
- 12.9 Lupin Pharmaceuticals
- 12.9.1 Lupin Pharmaceuticals Company Information
- 12.9.2 Lupin Pharmaceuticals Business Overview
- 12.9.3 Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.9.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
- 12.9.5 Lupin Pharmaceuticals Recent Developments
- 12.10 Dainippon Sumitomo Pharma
- 12.10.1 Dainippon Sumitomo Pharma Company Information
- 12.10.2 Dainippon Sumitomo Pharma Business Overview
- 12.10.3 Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio
- 12.10.5 Dainippon Sumitomo Pharma Recent Developments
- 12.11 Basilea Pharmaceutica International AG
- 12.11.1 Basilea Pharmaceutica International AG Company Information
- 12.11.2 Basilea Pharmaceutica International AG Business Overview
- 12.11.3 Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.11.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio
- 12.11.5 Basilea Pharmaceutica International AG Recent Developments
- 12.12 Allergan plc
- 12.12.1 Allergan plc Company Information
- 12.12.2 Allergan plc Business Overview
- 12.12.3 Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2021-2026)
- 12.12.4 Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio
- 12.12.5 Allergan plc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst